Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Ver. Summary Created by Modification Content Size Created at Operation
1 + 1504 word(s) 1504 2021-10-11 10:09:53 |
2 update references and keywords -4 word(s) 1500 2021-11-05 04:39:30 |

Video Upload Options

Do you have a full video?


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
De Vita, F. IALUSET VITAL® Cream Improves Adults Atopic Dermatitis. Encyclopedia. Available online: (accessed on 08 December 2023).
De Vita F. IALUSET VITAL® Cream Improves Adults Atopic Dermatitis. Encyclopedia. Available at: Accessed December 08, 2023.
De Vita, Fernanda. "IALUSET VITAL® Cream Improves Adults Atopic Dermatitis" Encyclopedia, (accessed December 08, 2023).
De Vita, F.(2021, November 04). IALUSET VITAL® Cream Improves Adults Atopic Dermatitis. In Encyclopedia.
De Vita, Fernanda. "IALUSET VITAL® Cream Improves Adults Atopic Dermatitis." Encyclopedia. Web. 04 November, 2021.
IALUSET VITAL® Cream Improves Adults Atopic Dermatitis

Atopic dermatitis (AD) is a chronic relapsing skin disease, associated with impaired skin barrier function and characterized by poorly defined pruritic, erythematous lesions. In this study, the efficacy of a new topical cream (IALUSET VITAL®), containing hyaluronic acid and the extract of Salvia haenkei, in reducing symptoms of moderate AD in adults was investigated. This study was a randomized, double blind, vehicle-controlled clinical study. Treatment efficacy was evaluated considering both objective parameters (Scoring Atopic Dermatitis, SCORAD) and subjective pa-rameters (Patient Oriented Eczema Measure, POEM, and an itching sensation) and through non-invasive bioengineering techniques to measure skin moisturization and Trans Epidermal Water Loss (TEWL).

atopic dermatitis hyaluronic acid cream SCORAD

1. Introduction

Atopic dermatitis (AD) is a chronic inflammatory skin disease, affecting up to 20% of children and up to 3% of adults [1], characterized by erythematous skin lesions with intense pruritus, a very disabling symptom that considerably impairs a patient’s quality of life. It is widely recognized that AD is a multifactorial disease, involving immune disorders, impaired skin barrier function and environmental factors. Nevertheless, a major debate exists as to whether AD is primarily driven by immune dysregulation (inside-out theory) or epidermal barrier dysfunction (outside-in theory) [2][3]. Common tracts of 10–40% of AD patients are the loss-of-function mutation of the FLG gene, encoding the structural epidermal protein filaggrin, contributing to epidermal barrier dysfunction [4][5] and a reduced content of ceramides, important water-holding molecules in the extracellular space in the horny layer [6]. These events lead to trans-epidermal water loss, a component of a physiological process known as perspiratio insensibilis, and increased permeability to allergens and pathogens and promotes inflammation stimulating the activation of the innate immune response. Cutaneous sensory nerves transmit the increased itch signal to the brain, which leads to further scratching and impairing of skin integrity with the establishment of a self-feeding vicious circle [2][7]. With regard to the treatment of AD, current therapies aim to clear inflamed lesions and reduce itch in order to improve patient’s everyday life. Topical therapies with emollients and anti-inflammatory drugs are the mainstay for mild-to-moderate AD; phototherapy and systemic immunomodulatory drugs can be effective in more-severe AD [8].
Hyaluronic acid (HA), a polysaccharide composed of alternating glucuronic acid and N-acetylglucosamine residues, is one of the main components of the extracellular matrix [9], especially in the skin that accounts for about 50% of the total content of HA in the body [10]. HA is a key factor in wound healing and tissue repair processes, being involved in proliferation, differentiation, and migration of keratinocytes [11][12][13], as well as in skin aging owing to its ability to retain water and moisturize skin [9]. In addition, evidence from animal studies have shown that HA is also involved in the establishment and homeostasis of epidermal skin barrier, regulating both epidermal differentiation and lipid synthesis/secretion through the interaction with its receptor CD44 [13][14]. In addition, clinical studies support the safety and the efficacy of hyaluronic acid-based emollient foam in treating patients with moderate AD [15][16].
Herbal extracts have been used for the treatment of skin diseases, among which AD, for centuries [17]. Recently, both in vitro and clinical studies have shown the efficacy of the extract of Salvia haenkei, a plant native of Bolivia largely used in traditional medicine [18], as an anti-aging agent [19][20]. In addition, an extract of Salvia haenkei has been patented both as re-epithelizing and cicatrizing agent [21] and as an active agent in the treatment of dermatological diseases [22].

2. Evaluation of the Efficacy of IALUSET VITAL® Cream in Helping the Improvement of the Atopic Dermatitis Symptoms in Adults

Atopic dermatitis is mainly characterized by dysfunctions of the skin barrier and an uncontrolled inflammatory response. HA has been shown to play an important role in regulating homeostasis of the skin, especially in maintaining selective permeability of the epidermis and controlling inflammatory response. Moreover, because of its hygroscopic property, HA provides a hydrated microenvironment which facilitates the transport of nutrients through the tissue [23]. Finally, HA directly affects the function of skin cells by mediating signaling events that control the proliferation/differentiation of keratinocytes and lamellar bodies production, important mechanisms for maintaining selective permeability and repair of the skin [11][13]. It was also demonstrated that topical application of HA induces keratinocyte proliferation/differentiation and increases epidermal thickness and skin barrier repair [14].
Immune response in subjects with AD is dysfunctional, characterized by the release of many pro-inflammatory cytokines, such as tumor necrosis factor (TNF) and interleukins [24]. Several authors have shown that HA reduces inflammatory response by downregulating the expression of pro-inflammatory and upregulating anti-inflammatory molecules [25][26][27][28][29]. Indeed, Kim et al. observed that HA decreases skin lesions in an atopic dermatitis model of DNFB-treated Nc/Nga mice [26].
In patients with AD, claudins’ expression levels are reduced [30][31]. These proteins together with the occludin form a family of proteins that are the most important components of the tight junctions (TJs). In turn, TJs are critical in the functioning of the skin barrier because defective TJs increase paracellular permeability, resulting in an enhanced flux of environmental factors such as irritants, microbial products, toxins, and allergens, which, crossing the skin surface, trigger the immune response [32]. Recently, the extract of Salvia haenkei was shown to increase occludin expression as well as to control the expression and localization of filaggrin, a key marker of keratinocytes’ differentiation. Thus, the extract of Salvia haenkei reinforces the adhesion between the cells and favors the maintenance of the barrier integrity [22].
Considering the mentioned observations, we performed this clinical study in order to assess on AD patients the efficacy of IALUSET VITAL® cream, a cosmetic containing two molecular weights of hyaluronic acid (300 kDa and 800 kDa) and the extract of Salvia haenkei.
This study clearly showed that the regular use of IALUSET VITAL® progressively and significantly reduces AD severity and improves SCORAD, POEM, itch, and stratum corneum moisturization scores. After one week of treatment, a significant decrease of the SCORAD index was already observed in the active group compared to the control group. Interestingly, IALUSET VITAL® treatment improved AD severity from moderate to a mild degree, in a time-dependent manner as shown by the progressive reduction of the mean change of SCORAD index from baseline by 42% compared with 25% induced by vehicles in the control group at week 4.
At the end of treatment, 70% and 65% of the patients in the active and control group, respectively, reported a reduction of the POEM score less than the median value at T0. In particular, only the active group showed 10% of patients with total remission of symptoms.
As concerns the evaluation of itching sensation, immediately after treatment, 80% and 65% of the patients in the active and control group, respectively, showed a reduction of itch score less than the median value at T0. Moreover, 60 min after the treatment, a reduction of itch score lower than the median value at T0, was recorded in 100% and 95% of the patients in the active and control group, respectively.
However, both for POEM and itch score, the differences between the two treatment groups did not appear to be statistically significant.
The treatment with IALUSET VITAL® led to a significant increase of skin hydration throughout the treatment period while the vehicle induced a more variable effect in the control group. Paradoxically, although the TEWL analysis showed a positive trend of IALUSET VITAL®, in terms of effectiveness compared to vehicles, no statistically significant difference has been shown. Similar findings have been reported in other studies on moisturizers [33][34][35]. Our results may not be consistent for several reasons. Firstly, the relationship between skin dryness and TEWL is complex, whereby changes in dryness may not necessarily reflect simultaneous changes in TEWL [36]. Then, standardization of TEWL measurements can be technically difficult, while corneometer is an effective and sensitive tool to determine skin moisturization [37]. Therefore, the latter method is more sensitive to measure the skin barrier function than TEWL in AD patients and a larger sample size may be necessary to clarify this discrepancy and achieve a statistically significant trend in TEWL changes.
The vehicle used in this study was an emollient base cream, with the same composition of IALUSET VITAL® except for the key ingredients hyaluronic acid and extract of Salvia haenkei. Due to the presence in the formulation of some humectant and emollient agents such as xylitylglucoside, anhydroxylitol, xylitol, isononyl isononanoate, coco caprylate/caprate, and l-arginine, the vehicle cream exhibits some beneficial moisturizing effects that should be taken into consideration when statistically significant differences in effectiveness between the active and control group have not been noted. Indeed, it is well known that emollients make the epidermis softer and more pliable, and they are effective in increasing skin hydration, improving barrier function, and reducing itching in AD [38].
Thus, the efficacy of IALUSET VITAL® is guaranteed by the good emollient properties resulting from a well-designed basic formulation and, above all, the addition of active ingredients hyaluronic acid and extract of Salvia haenkei that greatly increase its effectiveness. In addition, IALUSET VITAL® cream was well-tolerated by patients. Overall, this entry clearly shows that IALUSET VITAL® has a good safety profile and promotes the relief of the most common signs and symptoms of moderate AD, rapidly suppressing itch and reducing eczema severity.


  1. Nutten, S. Atopic Dermatitis: Global Epidemiology and Risk Factors. Ann. Nutr. Metab. 2015, 66 (Suppl. 1), 8–16.
  2. Ständer, S.; Metz, M.; Ramos, M.; Maurer, M.; Schoepke, N.; Tsianakas, A.; Zeidler, C.; Luger, T.A. Anti-pruritic Effect of Sertaconazole 2% Cream in Atopic Dermatitis Subjects: A Prospective, Randomized, Double-blind, Vehicle-controlled, Multi-centre Clinical Trial of Efficacy, Safety and Local Tolerability. Acta Derm. Venereol. 2014, 96, 792–796.
  3. Brunello, L. Atopic dermatitis. Nat. Rev. Dis. Primer 2018, 4, 2.
  4. Cabanillas, B.; Novak, N. Atopic dermatitis and filaggrin. Curr. Opin. Immunol. 2016, 42, 1–8.
  5. Kono, M.; Nomura, T.; Ohguchi, Y.; Mizuno, O.; Suzuki, S.; Tsujiuchi, H.; Hamajima, N.; McLean, W.H.I.; Shimizu, H.; Akiyama, M. Comprehensive screening for a complete set of Japanese-population-specific filaggrin gene mutations. Allergy 2014, 69, 537–540.
  6. Ishikawa, J.; Narita, H.; Kondo, N.; Hotta, M.; Takagi, Y.; Masukawa, Y.; Kitahara, T.; Takema, Y.; Koyano, S.; Yamazaki, S.; et al. Changes in the Ceramide Profile of Atopic Dermatitis Patients. J. Investig. Dermatol. 2010, 130, 2511–2514.
  7. Novak, N.; Simon, D. Atopic dermatitis—From new pathophysiologic insights to individualized therapy. Allergy 2011, 66, 830–839.
  8. Hajar, T.; Gontijo, J.R.V.; Hanifin, J.M. New and developing therapies for atopic dermatitis. Bras. Dermatol. 2018, 93, 104–107.
  9. Papakonstantinou, E.; Roth, M.; Karakiulakis, G. Hyaluronic acid: A key molecule in skin aging. Dermatoendocrinol 2012, 4, 253–258.
  10. Reed, R.K.; Lilja, K.; Laurent, T.C. Hyaluronan in the rat with special reference to the skin. Acta Physiol. Scand. 1988, 134, 405–411.
  11. Maytin, E.V.; Chung, H.H.; Seetharaman, V.M. Hyaluronan participates in the epidermal response to disruption of the permeability barrier in vivo. Am. J. Pathol. 2004, 165, 1331–1341.
  12. Passi, A.; Sadeghi, P.; Kawamura, H.; Anand, S.; Sato, N.; White, L.E.; Hascall, V.C.; Maytin, E.V. Hyaluronan suppresses epidermal differentiation in organotypic cultures of rat keratinocytes. Exp. Cell Res. 2004, 296, 123–134.
  13. Bourguignon, L.Y.W.; Ramez, M.; Gilad, E.; Singleton, P.A.; Man, M.-Q.; Crumrine, D.A.; Elias, P.M.; Feingold, K.R. Hyaluronan–CD44 Interaction Stimulates Keratinocyte Differentiation, Lamellar Body Formation/Secretion, and Permeability Barrier Homeostasis. J. Investig. Dermatol. 2006, 126, 1356–1365.
  14. Bourguignon, L.Y.W.; Wong, G.; Xia, W.; Man, M.-Q.; Holleran, W.M.; Elias, P.M. Selective matrix (hyaluronan) interaction with CD44 and RhoGTPase signaling promotes keratinocyte functions and overcomes age-related epidermal dysfunction. J. Derm. Sci. 2013, 72, 32–44.
  15. Hebert, A.; Pacha, O. Treating atopic dermatitis: Safety, efficacy, and patient acceptability of a ceramide hyaluronic acid emollient foam. Clin. Cosmet. Investig. Dermatol. 2012, 5, 39.
  16. Draelos, Z.D. A clinical evaluation of the comparable efficacy of hyaluronic acid-based foam and ceramide-containing emulsion cream in the treatment of mild-to-moderate atopic dermatitis: Barrier restoration therapy in atopic dermatitis. J. Cosmet. Dermatol. 2011, 10, 185–188.
  17. Reuter, J.; Wölfle, U.; Weckesser, S.; Schempp, C. Which plant for which skin disease? Part 1: Atopic dermatitis, psoriasis, acne, condyloma and herpes simplex. J. Dtsch. Dermatol. Ges. 2010, 8, 788–796.
  18. Canaviri, C.; María, A. Medicina Tradicional y la Medicina Occidental en el Manejo de la Tuberculosis Municipio Caranavi Primer Semestre 2006. Ph.D. Dissertation, Universidad Mayor de San André, La Paz, Bolivia, 2007; p. 78.
  19. Matic, I.; Revandkar, A.; Chen, J.; Bisio, A.; Dall’Acqua, S.; Cocetta, V.; Brun, P.; Mancino, G.; Milanese, M.; Mattei, M.; et al. Identification of Salvia haenkei as gerosuppressant agent by using an integrated senescence-screening assay. Aging 2016, 8, 3223–3236.
  20. Cestone, E.; Bellia, G.; Nobile, V.; Giori, A.M.; Alimonti, A.; Montopoli, M. Evaluation of the anti-ageing efficacy of Hilow Haenkenium cream in healthy woman. Aesthetic. Med. 2020, 6, 9.
  21. Alimonti, A.; Giori, A.M.; Montopoli, M.; Cadau, J. Use of a Vegetal Extract as an Active Agent in Tissue Re-Epithelizing and Cicatrizing Processes . WO2019121425 (A1). Available online: (accessed on 21 April 2020).
  22. Alimonti, A.; Giori, A.M.; Montopoli, M.; Cadau, J. Use of a Vegetal Extract as an Active Agent in the Treatment of Dermatological Diseases . WO2019121427 (A1). Available online: (accessed on 21 April 2020).
  23. Chen, W.Y.; Abatangelo, G. Functions of hyaluronan in wound repair. Wound Repair Regen. 1999, 7, 79–89.
  24. Otsuka, A.; Nomura, T.; Rerknimitr, P.; Seidel, J.A.; Honda, T.; Kabashima, K. The interplay between genetic and environmental factors in the pathogenesis of atopic dermatitis. Immunol. Rev. 2017, 278, 246–262.
  25. Neuman, M.G.; Nanau, R.M.; Oruña, L.; Coto, G. In vitro anti-inflammatory effects of hyaluronic acid in ethanol-induced damage in skin cells. J. Pharm. Pharm. Sci. 2011, 14, 425–437.
  26. Kim, Y.; Lee, Y.-S.; Hahn, J.-H.; Choe, J.; Kwon, H.J.; Ro, J.Y.; Jeoung, D. Hyaluronic acid targets CD44 and inhibits FcepsilonRI signaling involving PKCdelta, Rac1, ROS, and MAPK to exert anti-allergic effect. Mol. Immunol. 2008, 45, 2537–2547.
  27. Takahashi, K.; Goomer, R.S.; Harwood, F.; Kubo, T.; Hirasawa, Y.; Amiel, D. The effects of hyaluronan on matrix metalloproteinase-3 (MMP-3), interleukin-1beta (IL-1beta), and tissue inhibitor of metalloproteinase-1 (TIMP-1) gene expression during the development of osteoarthritis. Osteoarthr. Cartil. 1999, 7, 182–190.
  28. Campo, G.M.; Avenoso, A.; Nastasi, G.; Micali, A.; Prestipino, V.; Vaccaro, M.; D’Ascola, A.; Calatroni, A.; Campo, S. Hyaluronan reduces inflammation in experimental arthritis by modulating TLR-2 and TLR-4 cartilage expression. Biochim. Biophys. Acta 2011, 1812, 1170–1181.
  29. Mangano, K.; Vergalito, F.; Mammana, S.; Mariano, A.; De Pasquale, R.; Meloscia, A.; Bartollino, S.; Guerra, G.; Nicoletti, F.; Di Marco, R. Evaluation of hyaluronic acid-P40 conjugated cream in a mouse model of dermatitis induced by oxazolone. Exp. Med. 2017, 14, 2439–2444.
  30. De Benedetto, A.; Rafaels, N.M.; McGirt, L.Y.; Ivanov, A.I.; Georas, S.N.; Cheadle, C.; Berger, A.E.; Zhang, K.; Vidyasagar, S.; Yoshida, T.; et al. Tight junction defects in patients with atopic dermatitis. J. Allergy Clin. Immunol. 2011, 127, 773–786.e1–7.
  31. Nadeau, P.; Henehan, M.; De Benedetto, A. Activation of protease-activated receptor 2 leads to impairment of keratinocyte tight junction integrity. J. Allergy Clin. Immunol. 2018, 142, 281–284.e7.
  32. Sugita, K.; Kabashima, K. Tight junctions in the development of asthma, chronic rhinosinusitis, atopic dermatitis, eosinophilic esophagitis, and inflammatory bowel diseases. J. Leukoc. Biol. 2020, 107, 749–762.
  33. Hon, K.L.; Wang, S.S.; Lau, Z.; Lee, H.C.; Lee, K.K.C.; Leung, T.F.; Luk, N.M. Pseudoceramide for childhood eczema: Does it work? Hong Kong Med. J. 2011, 17, 132–136.
  34. Hon, K.L.E.; Ching, G.K.; Leung, T.F.; Choi, C.Y.; Lee, K.K.C.; Ng, P.C. Estimating emollient usage in patients with eczema. Clin. Exp. Dermatol. 2010, 35, 22–26.
  35. Hon, K.L.; Pong, N.H.; Wang, S.S.; Lee, V.W.; Luk, N.M.; Leung, T.F. Acceptability and efficacy of an emollient containing ceramide-precursor lipids and moisturizing factors for atopic dermatitis in pediatric patients. Drugs RD 2013, 13, 37–42.
  36. Lodén, M.; Andersson, A.C.; Andersson, C.; Frödin, T.; Oman, H.; Lindberg, M. Instrumental and dermatologist evaluation of the effect of glycerine and urea on dry skin in atopic dermatitis. Ski. Res. Technol. 2001, 7, 209–213.
  37. Son, S.W.; Park, S.Y.; Ha, S.H.; Park, G.M.; Kim, M.G.; Moon, J.S.; Yoo, D.S.; Oh, C.H. Objective evaluation for severity of atopic dermatitis by morphologic study of skin surface contours. Ski. Res. Technol. 2005, 11, 272–280.
  38. Hon, K.L.; Kung, J.S.C.; Ng, W.G.G.; Leung, T.F. Emollient treatment of atopic dermatitis: Latest evidence and clinical considerations. Drugs Context 2018, 7, 212530.
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to :
View Times: 463
Revisions: 2 times (View History)
Update Date: 05 Nov 2021